10x Genomics, Inc. Class A Common Stock
Here’s whether 10x Genomics, Inc. Class A Common Stock (TXG) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.50% over 10 days); RSI 45 — healthy momentum range; strong 1-year return of +176.9%; 3-month momentum positive (+12.4%); rising volume confirms the move (1.16x 30d avg). Currently 15.2% off its 52-week high. Score: +8/7.
TXG is in a confirmed uptrend, trading above both its 50-day ($21.32) and 200-day ($16.94) moving averages. An RSI of 45.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +176.9% compares to +22.9% for SPY (beat the market by 154.1%).